BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  GeneCentric Therapeutics Announces Publication of New Results Showing Clinical Benefit of RNA-based Antifolate Predictive Response Signature (AF-PRS) to Guide Lung Cancer Treatment Selection

  GeneCentric Therapeutics announced today the publication of initial results from the ongoing Piedmont study using real-world data in lung cancer to develop its novel RNA-based Antifolate Predictive Response Signature (AF-PRS), which is being co-developed as a clinical diagnostic test with Labcorp.

  July 20, 2023

   · 

  4 min read
• Business

  Quanterix to Report Second Quarter 2023 Financial Results on August 8, 2023

  Quanterix Corporation today announced that it will report financial results for the second quarter 2023 before the market opens on Tuesday, August 8, 2023, and will host a webcast and conference call on the same day at 8:30 a.m. E.T.

  July 20, 2023

   · 

  1 min read
• Drug Development

  Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients

  Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that its recently concluded phase 4 trial (NCT04566692) evaluating a biweekly dosing of XEMBIFY® has met its primary endpoint.

  July 20, 2023

   · 

  10 min read
• Biotech Bay

  Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana

  Guardant Health, Inc., a leading precision oncology company, announced that Blue Cross and Blue Shield of Louisiana now offers coverage for the Guardant Reveal™ molecular residual disease test.

  July 20, 2023

   · 

  4 min read
• Business

  Fortrea Announces Date for Second Quarter 2023 Financial Results and Conference Call

  Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2023 financial results before the market opens on Monday, August 14, 2023.

  July 20, 2023

   · 

  1 min read